




Clinically proven



Covered single  
stent design



Exceptional  
deliverability



Technical data /  
ordering info

**Teleflex**<sup>TM</sup>

Empowering the future of healthcare

# PK Papyrus<sup>TM</sup>

Covered coronary  
stent system

Designed to save lives when seconds count.



# PK Papyrus™

Designed to save lives when seconds count.<sup>1,2</sup>

Clinically proven<sup>a,3-15</sup>

**>1,500**

patients with PK Papyrus™ studied in clinical studies<sup>16</sup>

**10**

Number of publications available<sup>3-12</sup>

**93.7 %**

Patients were not referred to emergency cardiac surgery.<sup>b,7</sup> PK Papyrus™ is safe and effective as confirmed by one of the largest patient datasets for covered stents<sup>c,7</sup>

PK Papyrus™ bears the CE mark and is fully certified in accordance with the MDR, FDA<sup>d</sup>, and PMDA.


## Covered single stent design

Unique manufacturing method allows for an ultra thin membrane capable of sealing vessel perforations<sup>1</sup> and achieve a true covered single stent design<sup>1</sup>. Expect a high performing platform with an ultra thin membrane to deliver like a conventional stent.<sup>1</sup>



**PK Papyrus™**  
Single stent design

## Overexpansion diameters



NP: Nominal Pressure; RBP: Rated Burst Pressure; OD: Overexpansion Diameter.  
Balloon exchange required.

\*Guide Catheter Compatibility


The elastic membrane does not impair stent expansion.<sup>1</sup>

## Exceptional deliverability<sup>e,1,3</sup>

### Consistently high stent delivery success<sup>f,3-7</sup>


PK Papyrus™ is associated with reliable delivery (97.7 % stent delivery success) and successful sealing (92.1 %), favored by its unique design.<sup>7</sup>

#### Trackability




Enhanced Track<sup>17</sup>

#### Pushability



Better Push<sup>17</sup>

#### Flexibility in crimped state




High Flexibility<sup>g,17</sup>

#### Device technology


**Low crossing profile<sup>1</sup>**  
23 % reduction in crossing profile compared to the traditional sandwich design stent.<sup>19</sup>

PK Papyrus™ features a design with exceptional deliverability<sup>e,1</sup>, built on the same Orsiro™ Mission™ stent platform<sup>h,1</sup>, one of the most studied drug-eluting stents<sup>18</sup>.

**Cover material**  
Highly elastic polyurethane (PU) membrane.<sup>1</sup>



Polyurethane fibers (2000×)



#### 5F Compatibility

For main sizes – no need for guide catheter upgrade (Ø 2.5–4.0 mm).

5F

# PK Papyrus™

Indicated for acute coronary artery perforations.<sup>1</sup>

Vascular  
Intervention  
Coronary



## Technical Data

### STENT

Stent cover material	Non-woven, electrospun polyurethane
Stent strut thickness	Ø 2.5–3.0 mm: 60 µm (0.0024"); Ø 3.5–4.0 mm: 80 µm (0.0031"); Ø 4.5–5.0 mm: 120 µm (0.0047")
Stent material	Cobalt chromium (L-605) with <b>proBIO™</b> (Amorphous Silicon Carbide) coating
Maximum stent expansion diameter	Ø 2.5–3.0 mm: 3.50 mm; Ø 3.5–4.0 mm: 4.65 mm; Ø 4.5–5.0 mm: 5.63 mm

### DELIVERY SYSTEM

Guide wire diameter	0.014"
Usable catheter length	140 cm
Recommended guide catheter	Ø 2.5–4.0 mm: 5F (min. I.D. <sup>**</sup> 0.056"); Ø 4.5–5.0 mm: 6F (min. I.D. <sup>**</sup> 0.070")
Nominal pressure (NP)	Ø 2.5–3.5 mm: 8 atm; Ø 4.0–5.0 mm: 7 atm
Rated burst pressure (RBP)	Ø 2.5–4.0 mm: 16 atm; Ø 4.5–5.0 mm: 14 atm

<sup>\*\*</sup>I.D. = Inner Diameter

## Ordering Information

STENT Ø	CATHETER LENGTH 140 CM; STENT LENGTH			
	15 mm	20 mm	26 mm	
5F	<b>2.5 mm</b>	369380	369386	-
	<b>3.0 mm</b>	369381	369387	381789
	<b>3.5 mm</b>	369382	369388	381790
	<b>4.0 mm</b>	369383	369389	381791
	<b>4.5 mm</b>	369384	369390	369392
6F	<b>5.0 mm</b>	369385	369391	369393

### References:

- 1 Data on file.
- 2 Al-Lamee R, et al. Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. *JACC: Cardiovasc Interv.* 2011 Jan; 4(1):87-95.
- 3 Hernandez-Enriquez M, et al. Outcomes after use of covered stents to treat coronary artery perforations. Comparison of old and new-generation covered stents. *J Interv Cardiol.* 2018; 1-7.
- 4 Harnek J, James SK, Lagerqvist BO, et al. Very long-term outcome of coronary covered stents: a report from the SCAAR registry. *EuroIntervention.* 2019; 14: 1660-1667. doi: 10.4244/EIJ-D-18-00855.
- 5 Birkemeyer R, Olivencia G.K, Helling F, et al. Sealing of coronary perforations with a second-generation covered stent graft - Results from the PAST-PERF registry. *Cardiovascular Revascularization Medicine.* 2020; doi: 10.1016/j.carrev.2020.10.012.
- 6 Kandzari DE, Birkemeyer R. PK Papyrus covered stent: Device description and early experience for the treatment of coronary artery perforations. *Catheter Cardiovasc Interv.* 2019;1-5. doi.org/10.1002/ccd.28306.
- 7 Kandzari D.E, Sarao R.C. and Waksman R. Clinical experience of the PK Papyrus covered stent in patients with coronary artery perforations: Results from a multi-center humanitarian device exemption survey. *Cardiovascular Revascularization Medicine.* 2022. doi: 10.1016/j.carrev.2022.04.009.
- 8 Nagaraja V, Schwarz K, et al. Outcomes of patients who undergo percutaneous coronary intervention with covered stents for coronary perforation: A systematic review and pooled analysis of data. *Catheter Cardiovasc Interv.* 2019; 1-7. DOI: 10.1002/ccd.28646.
- 9 Hernandez-Enriquez et al. Use and outcomes of the PK Papyrus covered stent in France: SOS PK Papyrus registry. *Catheter Cardiovasc Interv.* 2020; doi: 10.1002/ccd.29328.
- 10 Wańka W, Januszek R, Kołodziejczak M, Kuźma Ł, Tajska M, Figatowski T, et al. Procedural and 1-year outcomes following large vessel coronary artery perforation treated by covered stents implantation: Multicentre CRACK registry. *PLoS ONE.* 2021; 16(5): e0249698. doi: 10.1371/journal.pone.0249698.
- 11 Bossard, M., Maria Cioffi G., et al. "Burying" covered coronary stents under drug-eluting stents: A novel approach to ensure long-term stent patency. *Cardiology Journal.* 2023, 30(2), 196-198. https://doi.org/10.5603/CJ.a2022.0116.
- 12 Jurado-Roman A, et al. Clinical outcomes after implantation of polyurethane-covered cobalt-chromium stents. Insights from the Papyrus-Spain registry. *Cardiovascular Revascularization Medicine* 2020 Aug; S1553-8389(20)30486-3. doi: 10.1016/j.carrev.2020.08.017. Online ahead of print.
- 13 Kufner S, et al. Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. *Catheter Cardiovasc Interv.* 2018; 1-9. DOI: 10.1002/ccd.27979.
- 14 Voll F, Koch T, Tölg R, Lenz T, Schroeter M, Lenders G, Hokken R, Casse S, Xhepa E, Schunkert H, Kastrati A, Kufner S. Clinical safety and efficacy of new-generation single-layer polytetrafluoroethylene covered coronary stents. *Cardiovasc Revasc Med.* 2023;1-7.
- 15 Azzalini, L., Poletti, E., Ayoub, M., Ojeda, S., Zivelonghi, C., La Manna, A., Bellini, B., Lostalo, A., Luque, A., Venuti, G., Montorfano, M., Agostoni, P., Pan, M., Carlini, M., & Mashayekhi, K. Coronary artery perforation during chronic total occlusion percutaneous coronary intervention: Epidemiology, mechanisms, management, and outcomes. *EuroIntervention.* 2019. https://doi.org/10.4244/EIJ-D-19-00282.
- 16 Overview of clinical trials based on an intensive literature research including sponsored and IITs for CAP patient number treated with PK Papyrus covered coronary stent system, Data as of July 2022 - Data on file.
- 17 Data on file, IIB data 2020, PK Papyrus Ø 3.0, 15 mm vs. BeGraft Coronary Stent Graft System Ø 3.0, 16 mm.
- 18 In large RCTs, based on Taglioni N, et al. Target lesion failure with current drug-eluting stents evidence from a comprehensive network meta-analysis. *JACC.* 2020.
- 19 Compared to Graftmaster 2.8/16, (Data on file).

<sup>a</sup>More clinical studies including larger number of patients reporting clinical outcomes with longer follow-up time than BeGraft Coronary Stent Graft System; <sup>b</sup>In 93.7 % of coronary artery perforation cases; <sup>c</sup>Based on the clinical experience of the PK Papyrus covered stent in patients with coronary artery perforations: results from the multi-center humanitarian device exemption survey. *Cardiovascular Revascularization Medicine.* 2021; <sup>d</sup>Humanitarian Device Exemption; <sup>e</sup>Compared to Jostent Graftmaster; <sup>f</sup>Based on over a 1,000 patients treated with PK Papyrus covered coronary stent system, Clinical program as of July 2022 Data on file; <sup>g</sup>In crimped state; <sup>h</sup>Based on up to 4.0 diameter; <sup>i</sup>Indication as per IFU.

Teleflex, the Teleflex logo, Orsiro, Orsiro Mission, PK Papyrus, and proBIO are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. All other names are the trademarks or registered trademarks of their respective owners.

© 2025 Teleflex Incorporated. All rights reserved.

394771-EN · REV J · 11 25 PDF · DV

### Distributed by:

Teleflex Headquarters International, Ireland · Teleflex Medical Europe Ltd. · IDA Business & Technology Park  
Dublin Road · Athlone · Co Westmeath · Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · orders.intl@teleflex.com

United Kingdom Tel. +44 (0)14 94 53 27 61 · info.uk@teleflex.com

South Africa Tel. +27 (0)11 807 4887 · assist.africa@teleflex.com

teleflex.com

Teleflex  
Empowering the future of healthcare